Niagen Bioscience (NAGE) Balance Sheet: Assets & Liabilities

Niagen Bioscience (NAGE) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Niagen Bioscience reported total assets of $106.41M and total liabilities of $29.87M. Shareholders' equity was $76.53M, up 66.0% from $46.09M a year earlier. Total debt stood at $2.82M against $64.64M in cash and short-term investments, a net cash position of $61.82M. That puts debt-to-equity at 0.04, compared with 0.06 a year earlier.

Niagen Bioscience Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Niagen Bioscience, Inc. (NAGE) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	64.64	44.51	27.17	20.29	28.02	16.50	18.61	22.42	45.39
Cash & Short-Term Investments	64.64	44.51	27.17	20.29	28.02	16.50	18.61	22.42	45.39
Accounts Receivable	9.74	7.77	5.23	8.48	5.23	2.69	2.18	4.42	5.34
Inventory	20.42	9.19	14.53	14.68	13.60	11.68	11.54	8.25	5.80
Other Current Assets	1.31	2.63	2.45	2.97	2.06	1.15	1.20	1.45	0.66
Total Current Assets	96.81	64.10	49.53	46.57	48.91	32.22	33.52	36.53	57.18
Non-Current Assets
Property, Plant & Equipment (Net)	3.52	3.45	4.54	6.32	7.36	4.43	4.66	3.59	2.87
Intangible Assets	5.66	0.36	0.51	0.67	0.86	1.08	1.31	1.55	1.65
Other Non-Current Assets	0.43	0.37	0.38	0.50	0.72	0.63	0.76	0.57	1.02
Total Non-Current Assets	9.60	4.18	5.43	7.49	8.94	6.14	6.73	5.70	5.55
Total Assets	106.41	68.28	54.96	54.06	57.84	38.36	40.25	42.23	62.72
Current Liabilities
Accounts Payable	10.80	8.53	10.23	9.68	10.42	9.45	9.63	9.55	3.72
Short-Term Debt	1.00	0.99	0.70	0.70	0.55	0.62	0.85	0.17	0.20
Accrued Liabilities	7.72	7.82	9.49	7.34	6.48	6.13	-	-	-
Deferred Revenue	0.40	0.61	0.20	0.16	0.16	0.28	0.17	0.28	0.31
Other Current Liabilities	8.12	7.82	9.49	7.34	6.48	6.13	4.42	4.44	3.86
Total Current Liabilities	19.92	17.95	20.62	17.87	17.61	16.48	15.06	14.44	8.09
Non-Current Liabilities
Long-Term Debt	1.82	1.66	2.58	3.56	4.15	1.02	0.87	0.14	0.31
Other Non-Current Liabilities	5.47	0.00	3.31	3.96	0.00	0.00	0.00	0.48	0.49
Total Non-Current Liabilities	9.95	4.24	5.89	7.52	8.50	5.46	4.74	0.61	0.80
Total Liabilities	29.87	22.18	26.51	25.39	26.11	21.93	19.80	15.05	8.89
Stockholders' Equity
Common Stock	0.08	0.08	0.08	0.07	0.07	0.06	0.06	0.06	0.06
Retained Earnings	-164.53	-181.91	-190.46	-185.49	-168.95	-141.83	-121.90	-89.75	-56.60
Accumulated Other Comprehensive Income	-0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Additional Paid-in Capital	240.99	227.93	218.85	214.09	200.61	158.19	142.29	116.88	110.38
Shares Outstanding	79.71	77.33	74.98	74.57	68.13	-	-	-	-
Total Stockholders' Equity	76.53	46.09	28.46	28.67	31.73	16.42	20.45	27.18	53.83
Total Liabilities & Equity	106.41	68.28	54.96	54.06	57.84	38.36	40.25	42.23	62.72

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Niagen Bioscience Balance Sheet

How much debt does Niagen Bioscience have?

Niagen Bioscience had total debt of $2.82M as of Dec 31, 2025, against $64.64M in cash and short-term investments. Its debt-to-equity ratio was 0.04. Total debt was $2.65M a year earlier.

What are Niagen Bioscience's total assets?

Niagen Bioscience reported total assets of $106.41M as of Dec 31, 2025, up 55.8% from $68.28M a year earlier. Total liabilities were $29.87M.

What is Niagen Bioscience's shareholders' equity?

Niagen Bioscience's shareholders' equity was $76.53M as of Dec 31, 2025, or about $0.96 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition